LTC2805723I2 - Kladribino režimas, skirtas išsėtinei sklerozei gydyti - Google Patents

Kladribino režimas, skirtas išsėtinei sklerozei gydyti

Info

Publication number
LTC2805723I2
LTC2805723I2 LTPA2018503C LTPA2018503C LTC2805723I2 LT C2805723 I2 LTC2805723 I2 LT C2805723I2 LT PA2018503 C LTPA2018503 C LT PA2018503C LT PA2018503 C LTPA2018503 C LT PA2018503C LT C2805723 I2 LTC2805723 I2 LT C2805723I2
Authority
LT
Lithuania
Prior art keywords
cladribin
regime
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
LTPA2018503C
Other languages
English (en)
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2805723(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of LTPA2018503I1 publication Critical patent/LTPA2018503I1/lt
Publication of LTC2805723I2 publication Critical patent/LTC2805723I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
LTPA2018503C 2004-12-22 2018-02-20 Kladribino režimas, skirtas išsėtinei sklerozei gydyti LTC2805723I2 (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
EP14001970.4A EP2805723B1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis
EP10182676.6A EP2263678B1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating early secondary progressive Multiple Sclerosis
EP05823474A EP1827461B1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
LTPA2018503I1 LTPA2018503I1 (lt) 2018-03-12
LTC2805723I2 true LTC2805723I2 (lt) 2022-04-25

Family

ID=36227798

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18151634.5T LT3332789T (lt) 2004-12-22 2005-12-20 Kladribino režimas, skirtas išsėtinės sklerozės gydymui
LTPA2018503C LTC2805723I2 (lt) 2004-12-22 2018-02-20 Kladribino režimas, skirtas išsėtinei sklerozei gydyti

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP18151634.5T LT3332789T (lt) 2004-12-22 2005-12-20 Kladribino režimas, skirtas išsėtinės sklerozės gydymui

Country Status (24)

Country Link
US (2) US7713947B2 (lt)
EP (6) EP1827461B1 (lt)
JP (7) JP5795456B2 (lt)
KR (1) KR20070091662A (lt)
AR (1) AR052830A1 (lt)
AU (2) AU2005318190B2 (lt)
BR (1) BRPI0517132B8 (lt)
CA (2) CA2588966C (lt)
CY (3) CY1112614T1 (lt)
DK (2) DK2805723T3 (lt)
EA (1) EA015799B1 (lt)
ES (1) ES2921858T3 (lt)
FR (1) FR18C1008I2 (lt)
HR (1) HRP20120228T1 (lt)
HU (2) HUE059133T2 (lt)
IL (2) IL183930A0 (lt)
LT (2) LT3332789T (lt)
LU (1) LUC00064I2 (lt)
MX (1) MX2007007610A (lt)
NO (1) NO20073813L (lt)
PL (3) PL1827461T3 (lt)
SG (1) SG160391A1 (lt)
SI (2) SI2805723T1 (lt)
WO (1) WO2006067141A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537605A (ja) * 2006-05-24 2009-10-29 メルク セローノ ソシエテ アノニム 多発性硬化症を治療するためのクラドリビン・レジメン
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
CA3083328A1 (en) * 2017-11-24 2019-05-31 Merck Patent Gmbh Cladribine regimen for use intreating progressive forms of multiple sclerosis
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
WO1996019230A1 (en) 1994-12-22 1996-06-27 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
EP1556400B1 (en) 2002-09-25 2013-05-01 Brigham Young University Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
BRPI0407781A (pt) * 2003-02-25 2006-02-14 Applied Research Systems aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes
PL1608344T3 (pl) 2003-03-28 2011-01-31 Ares Trading Sa Doustne formulacje kladrybiny
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
JP2009537605A (ja) * 2006-05-24 2009-10-29 メルク セローノ ソシエテ アノニム 多発性硬化症を治療するためのクラドリビン・レジメン

Also Published As

Publication number Publication date
HUE059133T2 (hu) 2022-10-28
LUC00064I1 (lt) 2018-02-14
AU2005318190A1 (en) 2006-06-29
FR18C1008I2 (fr) 2019-03-01
DK2805723T3 (da) 2018-01-29
CY2018006I2 (el) 2018-06-27
EP4070800A1 (en) 2022-10-12
JP2015180685A (ja) 2015-10-15
AR052830A1 (es) 2007-04-04
AU2005318190B2 (en) 2010-11-25
WO2006067141A1 (en) 2006-06-29
CY2018006I1 (el) 2018-06-27
CA3087419A1 (en) 2006-06-29
BRPI0517132B8 (pt) 2021-05-25
LTPA2018503I1 (lt) 2018-03-12
SI3332789T1 (sl) 2022-08-31
HUS1800009I1 (hu) 2018-05-02
BRPI0517132A (pt) 2008-09-30
CA2588966A1 (en) 2006-06-29
BRPI0517132B1 (pt) 2020-02-18
EP2275110B1 (en) 2013-07-10
AU2011200768B2 (en) 2012-09-13
HRP20120228T1 (hr) 2012-04-30
JP5908863B2 (ja) 2016-04-26
PL2805723T3 (pl) 2018-04-30
US7713947B2 (en) 2010-05-11
JP6430554B2 (ja) 2018-11-28
JP5795456B2 (ja) 2015-10-14
EP1827461A1 (en) 2007-09-05
IL212421A0 (en) 2011-06-30
EP2263678A3 (en) 2011-04-27
JP2008524313A (ja) 2008-07-10
EP2805723A1 (en) 2014-11-26
AU2011200768A1 (en) 2011-03-17
JP2018165271A (ja) 2018-10-25
EP2275110A2 (en) 2011-01-19
EP2275110A3 (en) 2011-04-27
MX2007007610A (es) 2007-08-03
EP2263678A2 (en) 2010-12-22
SG160391A1 (en) 2010-04-29
EP3332789B1 (en) 2022-04-06
EP3332789A1 (en) 2018-06-13
JP6092945B2 (ja) 2017-03-08
EP2263678B1 (en) 2014-06-11
FR18C1008I1 (lt) 2018-03-30
KR20070091662A (ko) 2007-09-11
JP2017101061A (ja) 2017-06-08
US20100203017A1 (en) 2010-08-12
LT3332789T (lt) 2022-07-25
CA3087419C (en) 2023-03-07
LUC00064I2 (lt) 2018-03-28
SI2805723T1 (en) 2018-02-28
JP2013216664A (ja) 2013-10-24
JP6290962B2 (ja) 2018-03-07
CA2588966C (en) 2020-07-21
EA200701221A1 (ru) 2008-02-28
NO20073813L (no) 2007-09-21
JP2020193206A (ja) 2020-12-03
PL1827461T3 (pl) 2012-07-31
IL212421A (en) 2014-01-30
IL183930A0 (en) 2007-10-31
CY1112614T1 (el) 2016-02-10
ES2921858T3 (es) 2022-09-01
DK3332789T3 (da) 2022-07-11
US20090081163A1 (en) 2009-03-26
CY1119790T1 (el) 2018-06-27
EA015799B1 (ru) 2011-12-30
US8377903B2 (en) 2013-02-19
JP2016138128A (ja) 2016-08-04
EP1827461B1 (en) 2012-02-29
EP2805723B1 (en) 2018-01-17
PL3332789T3 (pl) 2022-08-22

Similar Documents

Publication Publication Date Title
LTC2805723I2 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
NL1029015A1 (nl) Therapeutische verbindingen.
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
WO2006023651A3 (en) Extended treatment of multiple sclerosis
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
NO20070251A (no) Brønnbehandling
HK1113085A1 (en) Compounds, compositions and methods for the treatment of poxvirus infections
NO20070297A (no) Brønnbehandling
CY2200156T2 (el) Επεξεργασια λυματων
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
HK1203055A1 (en) Treatment for multiple sclerosis
DE602005015963D1 (de) Estergebundene makrolide, die sich für die behandlung von mikrobiellen infektionen eignen
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
NL1029418A1 (nl) Behandeling van koolwaterstoffen.
WO2009018551A3 (en) Therapeutic compounds
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
TR200604882A3 (tr) Örülü esya imalati için tertibat.
DE602007008759D1 (de) Pyrroloä1,2-aüimidazoldion zur behandlung von peripherer neurotoxizität durch chemotherapeutische mittel
GB0400802D0 (en) Compounds for the treatment of disease
ITBO20040803A1 (it) Apparecchiatura per la realizzazione di trattamenti antiparassitari.